<DOC>
	<DOC>NCT01908712</DOC>
	<brief_summary>The overall objective of this trial is to provide aftercare treatment with Lamazym and to evaluate the safety of repeated Lamazym i.v. treatment of subjects with alpha-Mannosidosis whom previously participated in Lamazym-trial.</brief_summary>
	<brief_title>Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients</brief_title>
	<detailed_description>This trial provide aftercare treatment with Lamazym to French patients.</detailed_description>
	<mesh_term>Mannosidase Deficiency Diseases</mesh_term>
	<mesh_term>alpha-Mannosidosis</mesh_term>
	<criteria>the subject must have participated in previous Lamazymtrials: phase 2b: 201100435540 or phase 3: 201200097917 Subject or subjects legally authorized guardian(s) must provide signed, informed consent prior to performing any trialrelated activities The subject and his/her guardian(s) must have the ability to comply with the protocol Presence of known clinically significant cardiovascular, hepatic, pulmonary, or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial Any other medical condition or serious intercurrent illness, or extenuating circumstances that, in the opinion of the Investigator, would preclude participation in the trial Pregnancy. Pregnant woman is excluded. Before start fot he treatment the investigators will for women of childbearing potential perform a pregnancy test and decide whether or not there is a need for contraception Psychosis; any psychotic disease, also in remission, is an exclusion criteria Planned major surgery that, in the opinion of the Investigator, would preclude participation in the trial Adult patients who, in the opinion of the Investigator, would be unable to give consent, and who does not have any legal protection or guardianship total IgE &gt; 800 IU/mL Known allergy to the IMP or any excipients (SodiumPhosphate, Glycine, Mannitol)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>